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Abstract
The careful scrutiny of drug delivery systems is essential to evaluate and justify their potential for
the clinic. Among the various studies necessary for pre-clinical testing, the impact of degradation
is commonly overlooked. In this paper, we investigate the effect of fabrication (porosity and
nucleation layer) and environment (buffer and pH) factors on the degradation kinetics of multi-
stage nanovectors (MSV) composed of porous silicon. The degradation by-products of MSV were
exposed to endothelial cells and analyzed for detrimental effects on cellular internalization,
architecture, proliferation, and cell cycle. Increases in porosity resulted in accelerated degradation
exhibiting smaller sized particles at comparable times. Removal of the nucleation layer (thin layer
of small pores formed during the initial steps of etching) triggered a premature collapse of the
entire central porous region of MSV. Variations in buffers prompted a faster degradation rate
yielding smaller MSV within faster time frames while increases in pH stimulated erosion of MSV
and thus faster degradation. In addition, exposure to these degradation by-products provoked
negligible impact on the proliferation and cell cycle phases on primary endothelial cells. Here, we
propose methods that lay the foundation for future investigations towards understanding the
impact of the degradation of drug delivery platforms.
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1. Introduction
In the past decade, porous silicon (pSi) has gained significant momentum within the
biomedical field due to desirable traits such as favorable degradability1, biocompatibility2,
and photoluminescence.3 These unique set of qualities allowed pSi to be applied to
applications ranging from optics4 and biosensors5 to microelectronics6 and tissue
engineering.7,8 Moreover, the flexible nature of pSi permits the adjustment of fabrication
parameters to modify precise characteristics (e.g., size, shape, surface, pore size) and has
made pSi particularly favorable for drug delivery applications. For example, by leveraging
the increased surface area and pore volume of pSi vectors, the secure attachment and
incorporation of various molecules, therapeutic moieties, and nanoparticles was successfully
achieved.9–11 This inherent versatility allowed pSi vectors to increase the bioavailability,
drug solubility, and provide prolonged release of various payloads.12
pSi has the unique ability to degrade completely yielding a bioinert13 silicic acid as its only
product. As demonstrated in previous studies, silicic acid is fundamental for normal bone
homeostasis and increased levels of silicic acid were well sustained within the body and
readily excreted through urine.14 In addition, advantageous health benefits have been
witnessed in silicic acid’s rare ability to reduce aluminum uptake and promote increased
excretion of aluminum in urine15 which can be beneficial for the prevention and progression
of Alzheimer’s disease.16 Previous studies have also demonstrated silicic acid’s ability to
stimulate the synthesis of collagen type 1 and promote osteoblastic differentiation.17 These
many advantages provided by pSi by-products allow pSi to be a suitable material for drug
delivery applications.
Thus by taking advantage of the numerous features of pSi, our group successfully
engineered18 and tested19–21 multi-stage nanovectors (MSV) whose primary objective was
to decouple the multiplicity of tasks required for the delivery of therapeutics to specific
locations and distribute them onto separate stages. Within this platform, pSi performs as the
first stage and is tasked to carry, protect, deliver, and release the second stage in an efficient
manner. The adjustment of fabrication parameters enables the creation of pore sizes ranging
from 3–100 nm in diameter to accommodate the loading of various sized payloads.18
Additionally, to ensure increased retention within the pores, a nucleation layer is
incorporated to prevent payloads from passing freely through the pores. Although both
properties serve to enable the greatest efficacy of a payload-loaded MSV, the characteristics
that regulate their degradation have yet to be fully investigated.
In addition to efficiency and safety, a major consideration for drug delivery systems is their
ability to be compatible within the body’s environmental conditions and maintain stability
for systemic administration. While previous work examined the degradation effect of
pegylation22 and biofluids23 on pSi, this work aims to investigate the degradation dynamics
of MSV to understand their stability at different porosities, removal of the nucleation layer,
and impact of buffer and pH. Furthermore, the consequences of MSV degradation by-
products on cellular architecture, proliferation, and cell cycle were explored. Herein, we
monitored the impact of fabrication (porosity, nucleation layer) and environmental (buffer,
pH) parameters on the degradation of MSV using Inductively Coupled Plasma - Atomic
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Emission Spectrometer (ICP-AES), scanning electron microscopy (SEM), flow cytometry,
and size and zeta potential analysis. In addition, the cyto-compatibility of MSV was assessed
using primary cells to assess detrimental effects on cell structure, proliferation, and cell
cycle.
2. Materials & Methods
2.1 MSV Fabrication
We previously reported how combining microfabrication with electrochemical etching
yielded the MSV18 used in this study (Figure 1). An initial deposition of a 120 nm thick
layer of silicon-rich silicon nitride (SiN) over a 100 mm p-type Si wafer (Figure 1A)
followed by photolithography yielded an array of 2 µm diameter holes with 2 µm pitch
(Figure 1B). Reactive ion etching (RIE) in CF4 gas formed 400 nm deep trenches in the Si
corresponding to the photolithographic holes (Figure 1C). Stripping of photoresist followed
by electrochemical etching with the SiN masking layer formed MSV in the 2 µm×400 nm
trenches (Figure 1D). The current profile during electrochemical etching and the
composition of the etch solution determined the porosity and shell thickness of the MSV. A
two-step current process yielded MSV with small to large pores (SP-LP, respectively, Figure
1C). The initial step used a lower current to form the nucleation layer and following host
layer. The nucleation layer was a < 50 nm thick layer of pores < 2 nm in diameter that
inevitably forms in the initial steps of electrochemical etch. A step up in current formed an
unstable pSi layer with high porosity between the host layer and the solid silicon substrate.
Once the electrochemical process was completed, the substrates were washed and dried in
N2. At this step it was possible to remove the nucleation layer, if desired, through a short
RIE in CF4 gas (Figure 1E). Release of MSV from the substrate was achieved by shattering
the release layer through sonication in isopropanol (Figure 1F). XLP MSV consisting
exclusively of a host layer were not mechanically stable, due to the >80% porosity of the
layer. For this reason the formation of MSV with XL pores instead required the initial
formation of a transitional layer with ~80nm thickness having pores of progressively
increasing diameter, which varied from that of the nucleation layer to that of the XLP host
layer (Figure 1C). To achieve this, an initial step with progressively increasing current was
introduced before the two-step current process. These studies were conducted using 3.2 ×
0.7 µm MSV with various porosities dependent on study.
2.2 Degradation of MSV
MSV with varying porosities and presence of a nucleation layer was studied by inducing
degradation in PBS under rotation using a LabQuake tube rotator at 10 rpm and 37 °C, pH
7.2.24 At pre-determined times, aliquots were removed from samples, centrifuged at 4200
rpm for 10 minutes, and supernatants were discarded. Aliquots were stored at 4 °C until
analysis could be performed. NP, SP, MP, LP, and XLP were used to study the effect of
porosity and MP were selected to study the contribution of a nucleation layer. Effect due to
buffers was investigated comparing Tris-HCl 20 mM pH 7.3 + 0.9% NaCl (Sigma-Aldrich)
as the ‘saline’ solution and Dulbecco’s modified eagle medium (GIBCO) supplemented with
10% fetal bovine serum (GIBCO) as the ‘cell culture media’ (CCM) solution. To investigate
the effect of buffer, SP and LP MSV were selected to have a range of MSV porosities tested.
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1.2 × 107 MSV (SP & LP) were suspended in 1.5 mL of saline or CCM solution, and
measured in triplicate. Degradation was studied as previously mentioned with samples under
rotation at 10 rpm at 37°C. One rotational speed was chosen to concentrate on the
differences between fabrication and environmental factors rather than the effect rotation may
have. The effect attributed to pH was investigated by adjusting 20 mM Tris-HCl to various
pH levels. 1.5 × 106 LP MSV were suspended in 1.5 mL of each pH and rotated at 37°C.
For flow cytometry, aliquots were re-suspended in deionized water and measured using a
BD FACSCalibur (BD Biosciences) and analyzed with CellQuest. For ICP-AES, aliquots
were placed in nylon centrifugal filter tubes (0.45 µm, VWR) and centrifuged for 10 minutes
at 4200 rpm. Samples were diluted 1:100 in water containing 1 ppm of Yttrium and
measured on a Varian Vista Pro Simultaneous Axial at the Geochemistry Laboratory at Rice
University. MSV size distribution and number were examined using the Z2™ COULTER
COUNTER® Cell and Particle Counter outfitted with a 50 µm ampoule aperture tube
(Beckman Coulter; Fullerton, CA). Samples were diluted into 1.0 mL of ISOTON and
counted using limits of 1.0 to 2.8 µm, with the resulting data exported to Excel. Samples for
SEM were washed twice in water to remove salts from samples and re-suspended in 25 µL
of water and placed in the center of an aluminum stage. Samples were left to dry overnight
in a vacuum desiccator. Images were taken on a Zeiss Neon 40 microscope equipped with an
in-lens detector. Zeta potential measurements were resuspended in 1.5 mL of filtered
monobasic PB (10 mM, pH 7.4) and measured using a ZetaPALS analyzer (Brookhaven
Instruments Corporation; Holtsville, NY).
2.3 Cell culture
Human Umbical Vein Endothelial Cells (HUVEC) were purchased from Lonza (Lonza
Group Ltd; Switzerland) and cultured in Clonetics ® EBM®-2 Endothelial Cell Growth
Medium-2 (Lonza; CC-3156) supplemented with EGM-2 SingleQuots® Kit (Lonza;
CC-4176). HUVEC were used between passages 4–10 for described experiments.
2.4 MTT & Cell cycle
For MTT, HUVEC were seeded in 96 well plates at 5,000 cells per plate. Degradation
byproducts collected from the supernatant of completely degraded MSV were added to each
well. At pre-determined times, wells were incubated with 3-[4,5-Dimethylthiazol-2-yl]-2,5-
Diphenyltetrazolium Bromide (MTT) at 0.5 mg/mL in complete media for two hours at 37
°C, 5% CO2 followed by an 30 minute incubation with DMSO and measured for absorbance
at 570 nm on a BioTek plate reader.
The effect on cell cycle after treatment with the by-products of degradation from MSV was
evaluated as previously described.25 Briefly, HUVEC were treated with SP or LP MSV
degraded by-products by completely degrading MSV and removing samples from the
degraded supernatant portion (i.e., not partially degraded MSV). At pre-determined times,
cells were collected and quickly fixed using 70% ethanol at 4°C for 10 minutes then stored
at −20°C for 30 minutes. A 50 µg/mL solution of propidium iodide (PI) was prepared in a 10
mM Tris buffer at pH 7.3 containing 5mM MgCl2. One mL of PI solution and 50 µL of a 1.5
mg/mL solution of RNAse I were slowly added under gentle agitation. Cells were incubated
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for 1 hour at 37 °C, followed by three washes PBS, re-suspended in 200 µL and analyzed
using a Becton Dickinson FACSCalibur.
2.5 HUVEC cytoskeletal staining
HUVEC were seeded into a chamber slide (LabTek) at 75,000 cells per well and allowed to
adhere overnight. The following day, HUVEC were treated with DyLightÆ 555 MSV at a
ratio of 1:10 and an equivalent amount of MSV fragments (i.e., partially degraded MSV) for
24 hours. HUVEC were then stained with AlexaFluor 488 Phalloidin (Invitrogen), mounted
with Pro Long Gold containing DAPI, and imaged using an inverted Nikon Eclipse Ti
microscope.
2.6 Statistical Analysis
All statistics were calculated using Prism GraphPad software. Zeta Potential values were
tested using a Two-Way ANOVA followed by a Bonferroni post-test to compare NP to SP
and MP. Nonlinear regression analysis fitted with a one phase association equation using the
least squares method was used to test significance in ICP-AES data (Figure 3D and Figure
4A). Constraints of Y0 at 0.0 and Plateau equal to 100 were used and the resulting rate
constants were compared using an extra sum of squares F test. For MTT results (Figure 6),
linear regression analysis was performed and significance was determined by testing
whether the slopes and intercepts were significantly different (F test). In all cases: * was
used for p-values between 0.01 to 0.05, ** for values between 0.001 to 0.01, and *** for
values < 0.001.
3.0 Results & Discussion
3.1 Impact of porosity on MSV degradation
The flexible nature of MSV allows for tunable porosity to accommodate a variety of
payloads and thus can have critical implications for drug delivery. This impact was studied
by comparing five different conditions (Table 1): NP (non-porous), SP (small pores), MP
(medium pores), LP (large pores), and XLP (extra large pores). Differences in degradation
profiles were investigated using size and zeta potential analysis at several times. Figure 2A
compared the volume distributions of various MSV at different time points. The
distributions were offset on the y-axis for clarity and to compare the changes in size at
different times. The initial peak at 1 fL was the detection limit of the instrument and was
common to all MSV examined. As MSV degraded, a shift in their volume towards the
detection peak is apparent for all MSV with the exception of NP. These shifts appeared
earlier for MSV with higher porosities and whose peaks progressed closer to the detection
limit at a faster rate. Figure 2B substantiates this claim by normalizing to zero hours and
plotting the modes (e.g., highest occurring number) collected during volume analysis. As
time increased, we observed the same trend as the volume graphs where the more porous
MSV displayed an overall smaller size at each time point while NP experienced minimal
changes in size. For example, at 24 hours the size of MSV had decreased by 37%, 56%,
62%, and 70%, respectively, for SP, MP, LP, and XLP.
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Zeta potential measurements were performed to determine the surface charge of MSV as
they degraded. Figure 2C diagramed the changes in surface charge of NP, SP, and MP MSV
during degradation. Due to their APTES modification, MSV were initially imparted with a
positive charge (+10–15 mV) and with time MSV became highly negative (−25–30 mV). At
eight hours, MSV reached a plateau of negative charge of −40mV and −35mV for NP and
SP/MP, respectively. By 24 hours, the surface charges of SP and MP were neutral while NP
remained negative (significantly different from SP and MP). Hence as the porosity of MSV
increased, an equivalent increase in degradation rate was observed. Surface charge
measurements revealed that the APTES surface modification quickly degraded and
exhibited a pattern such that the highest value was achieved at eight hours potentially
indicating the point where the highest surface area existed. On the other hand, the surface
charge measurements of NP MSV remained consistent confirming minimal degradation over
time.
3.2 Absence of nucleation layer and effect on pore structure
A critical function for MSV is to load and retain a nanoparticle payload within its porous
structure. The nucleation layer serves to prevent payloads from passing freely through MSV
and is typically associated with pore sizes less than 2 nm. We investigated the impact on
MSV degradation by comparing SEM, ICP-AES, flow cytometry, and size analysis. SEM
images illustrated that MSV without a nucleation layer (MSVxNL) began with larger pores
on the front-side while retaining the same overall shape compared to regular MSV (Fig 3A).
The overall shape of MSV and MSVxNL remained similar over time. However, we
observed that the porous structure of MSVxNL displayed significant remodeling such that
by 18 hours considerably larger pores were observed. This resulted in premature pore
instability ultimately triggering their complete collapse by 24 hours (Fig 3A). As shown in
Figure 3B, the size distribution of MSVxNL began with slightly smaller sizes consistent
with the earlier results of higher porosity MSV. The shifts in size over time associated with
MSVxNL were comparable to the variations observed in conventional MSV containing a
nucleation layer. Flow cytometry (Fig 3C) confirmed that MSVxNL size (forward scatter,
FSC) and shape (side scatter, SSC) degraded in a manner consistent with classical MSV.
FSC and SSC contour and 3D plots illustrated similar patterns with analogous shifts
accumulating at the origin of the graphs, indicative of MSV degradation between 24 and 48
hours. In addition, ICP-AES (Fig 3D) confirmed that MSVxNL had minimal effect on the
overall degradation of MSV as no significant increase in Si was detected in solution
determined using nonlinear regression analysis and comparing rate constants. The absence
of a nucleation layer from MSV had a negligible effect on their overall degradation pattern
resulting in comparable changes in size and shape. However, the porous structure of MSV
experienced a remarkable difference in their degradation displaying increased instability
generating increased porosity in the core of MSV resulting in complete pore collapse by 24
hours. Although the absence of a nucleation layer may negatively impact payload loading or
retention, it may be beneficial in order to achieve a quicker release rate attributed to the
quicker pore break-down observed.
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3.3 Degradation behavior of MSV in varying buffers
An understanding of the interplay between the local environment and the effect on the
degradation of drug delivery vectors is vital to gauge its use for systemic administration. To
this extent, we compared the degradation kinetics of MSV in two different types of buffers:
DMEM with 10% FBS (CCM) and Tris-HCl + 0.9% NaCl (Saline), both at pH 7.3. SP and
LP MSV were investigated to discover the impact of buffer on degradation using ICP-AES,
SEM, and size analysis. Figure 4A demonstrated that when suspended in CCM, the overall
degradation process was accelerated for both SP and LP. In CCM, SP reached a plateau of
maximum Si deposition by 24 hours, while in saline this was not achieved till 48 hours (90%
at 24 hours). Similarly, LP reached plateaus at 18 hours in CCM and 48 hours in saline (80%
at 24 hours). Nonlinear regression analysis revealed that MSV in CCM experienced a
significant acceleration in degradation rate, such that they degraded more than 3.5× faster in
CCM compared to saline for both SP and LP. Furthermore, SEM images (Fig 4B) confirmed
that both SP and LP degraded quicker in CCM compared to saline. In CCM, MSV exhibited
dramatic transformations in the overall appearance displaying smaller sized particles at 18
and 24 hours for SP and 12 versus 24 hours for LP. Figure 4C validated that dramatic shifts
in size were observed for MSV in different buffers. Both SP and LP in CCM experienced a
substantial shift within five hours resulting in acquisition of MSV predominantly at the
lower detection limit, which was not the case for MSV in saline. Thus, MSV exposed to
CCM revealed accelerated degradation kinetics resulting in substantial structural instability
and shifts in size compared to MSV in saline buffers. The addition of amino acids and serum
proteins commonly found in CCM26 and FBS possibly contributed to increased degradation.
The disparity between CCM and saline suggests that MSV will experience a significant
increase in degradation upon encountering sites rich in proteins, amino acids, and salts such
as the tissue and cellular microenvironment and during systemic blood circulation.
3.4 pH-induced degradation of MSV
Comprehension of the degradation phenomenon governing MSV in varying pH
environments is essential to ensure stability during systemic administration and upon
interactions within cellular environments. The influence of pH on MSV degradation was
investigated using a range from 9–12. In alkaline solutions, the adsorption of hydroxyl ions
on Si produces its dissolution into orthosilicic acid as the concentration of hydroxyl ions are
increased.27 This favors the formation of a bioinert neutral monomer of silicate ions as
equilibrium is reached that plays a beneficial role in the optimal growth of bone and
collagen.28 MSV degradation in alkaline conditions can be represented as shown in Figure
5A. In an aqueous solution, the hydroxyl layer of the MSV undergoes weak nucleophilic
attack by the water molecules. Increasing the pH of the solution, therefore, provides a
stronger nucleophilic attack that ultimately produces accelerated degradation of MSV into
silicic acid. As shown in Figure 5B, the contour plots acquired by flow cytometry displayed
progressive loss of organization of the overall shape and size of MSV as pH increased,
indicated by the increase of particles located outside the gating box. The ROI box within the
plots was used to monitor the extent of degradation, such that as MSV degrade their
distribution will extend outside of the box and drift towards the origin where small
fragments accumulate. MSV experienced substantial effects on the size and shape in 24 h
dependent on the pH used. At pH 12, MSV began drifting at 2.5 hours while at pH 10
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manifestations were not apparent until 20 hours. Next, we compared the total counts
collected by the flow cytometer at various times (Figure 5C). This was performed by fitting
the data using a plateau followed by a one-phase exponential decay constraining the plateau
to 0 and Y0 to 100, complete parameters detailed in supplementary information. At
increasing pH, MSV revealed an accelerated degradation with fewer MSV collected at
increasing pH levels. We fitted the data using a plateau followed by a one-phase exponential
decay constraining the plateau to 0 and Y0 to 100. This resulted in distinct degradation rate
constants of 0.053, 0.306, 0.638, 4.45 h−1 for pH 9, 10, 11, 12, respectively. In addition, this
model calculated delays in the initiation of degradation (X0) such that as the pH increased
the decay began earlier with times ranging from 1.2 to 8.6 hours. Taken together, this data
demonstrated that the increasing concentrations of hydroxide ions resulted in a rapid
degradation on the surface of MSV producing considerable structural modifications. As the
solution became more basic, the strength of the nucleophilic attack intensified resulting in an
overall increase in exposed pSi surface area and ultimately yielding the final product of
orthosilicic acid.
3.5 Cellular uptake and architecture
The concerns regarding the exposure of nanovectors to healthy cells must be adequately
examined in order to gauge its potential use in the clinic. We investigated the reaction of
HUVEC cultures upon introduction to partially degraded MSV (i.e. fragments). We initially
sought to understand the impact the internalization of fragments have on the cell
architecture, specifically inspecting the microfilaments of the cytoskeleton. Hence, we
compared the f-actin staining of HUVEC treated with equal concentrations of intact MSV
and MSV fragments. As shown in Figure 6A, the microtubules (green) and nucleus (blue) of
HUVEC displayed similar staining, comparing untreated and MSV. HUVEC exhibited
conserved parallel filamentous microfilament arrangements that assembled equally
throughout the entire cell. Previous studies demonstrated that MSV were quickly delivered
to the perinuclear region.25 Similarly, MSV fragments were found to preferentially
accumulate around the perinuclear area. Furthermore, nuclear staining revealed consistent
shapes upon internalization indicating a negligible cytotoxic effect attributed to fragments.
Thus, internalization of MSV degradation by-products exhibited a negligible effect on
cellular architecture producing conventional endothelial phenotypes.
3.6 Maintained cellular integrity
Understanding the potential consequences of complete degradation by-products on normal
cellular homeostasis is crucial for evaluating drug delivery vectors. The impact of
degradation products on the proliferation and cell cycle maintenance of HUVEC was
investigated by exposing cells to completely degraded MSV. The proliferation of HUVEC
was studied by comparing the incorporation of MTT to extrapolate the level of metabolic
activity. Degraded products from oxidized and APTES MSV exhibited similar proliferation
rates when compared to PBS controls (Fig. 6B). HUVEC displayed a resilient response to
the degradation by-products of MSV of varying porosities (SP, MP, LP, XLP) preserving an
active mitochondrial function. In addition, linear regression analysis revealed that the
proliferation rates (i.e., slopes) of HUVEC exposed to oxidized and APTES modified MSV
were not significantly different than the PBS control. The different porosities demonstrated
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that HUVEC tolerated a wide concentration of Si approximately ranging from 30 to 80 pg/
cell for XLP to SP, respectively.
Although comprehending the metabolic activity and continued proliferation of cells is
useful, it fails to provide detailed information on specific events occurring within cells upon
exposure. As shown in Figure 6C, we quantified the percentage of HUVEC within the
different phases of the cell cycle at 48 hours comparing the effect of degradation products
with different surface chemistry and porosities. HUVEC revealed equivalent patterns of
distribution across the phases at 48 hours with similar quantities among the different groups.
A comparison of these results with control and intact MSV25 revealed that at 48 hours
HUVEC exposed to the degradation products of MSV behaved nearly identical. Control
HUVEC displayed 17% in the sub G0 phase, commonly where apoptotic/inactive cells are
categorized, comparable with cells containing MSV degradation products whose values
ranged from 15–21%. Furthermore an inspection of combined effort of the G2/M and S
phases of the cycle, representative of mitotic and DNA replication, respectively, can be used
to chronicle the ‘active’ fraction of cell division. Using this benchmark, we confirmed that
HUVEC preserved these routine functions in a consistent manner displaying 32% for control
cells and ranging from 28–34% for MSV degradation. In addition, analogous HUVEC
percentages were discovered in the G0/G1 phase, which recognizes cells in the resting/
checkpoint stage. Hence, exposure to MSV degradation products yielded a negligible
cellular response from primary endothelial cells. In fact, we recently demonstrated that
intact MSV would permit HUVEC and stem cells to conserve their intrinsic functions (e.g.,
tube formation and multipotent differentiation) upon internalization confirming a higher
degree of biocompatibility.29 Here, HUVEC maintained proliferation and routine cycling
through various cellular phases without influencing DNA replication for several days after
the introduction of the degradation products.
4. CONCLUSION
In summary, we have reported how MSV were influenced by both fabrication and
environmental elements and how the degradation products affected normal cellular viability
and integrity. This study can potentially serve as a model on how to characterize drug
delivery vectors in order to achieve optimal degradation profiles while maintaining minimal
impact on biological systems. Variations in MSV porosity resulted in substantial shifts in
size and shape producing faster degrading MSV as the porosity increased. The removal of
the nucleation layer greatly impacted the stability of pore structure generating an early
collapse of the pores. Environmental influences also dictated how MSV would behave such
that buffers containing amino acids and proteins (e.g., cell culture media) and an increase in
pH facilitated quicker degradation of MSV. The degradation by-products of MSV were well
tolerated and exhibited minimal effect on the cellular architecture, proliferation, and cell
cycle progression of HUVEC. The work presented here establishes a precedent for future
studies to investigate the impact the degradation of drug delivery vectors has on biological
systems.
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Figure 1. Schematic representation of the MSV fabrication process
A) Fabrication began with a silicon rich silicon nitride layer. B) Patterning in CF4 yielded
an array of 2 µm diameter holes with pitch of 2 µm. C) A reactive ion etch formed pores
corresponding to photolithographic holes from the previous step. Graphs on right show the
effect of current applied over time for SP to LP (top) and XLP (bottom) with SEM images
depicting porosity. D) The optional removal of the nucleation layer was performed in a
reactive ion etch with CF4. E) MSV particles were released after etch with CF4.
Martinez et al. Page 12
J Biomed Mater Res A. Author manuscript; available in PMC 2015 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. Effect of porosity on degradation of MSV
A) Volume distributions of MSV with varying porosities are plotted at various times
comparing the shifts in size. Distributions are offset on the y-axis to highlight differences
between time points. B) The mode, or the value that appears most frequent, at each time
point is plotted and compared to other porosities of MSV. NP serves as control, as
degradation of non-porous silicon particles is minimal and was used for comparison. C) Zeta
potential measurements were used to provide insight on the surface charge of NP, SP, and
MP MSV. The results are shown as mean ± SD. Asterisks denote data points where the
difference was statistically significant compared to NP. * p < 0.05, ** p < 0.01, *** p <
0.001.
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Figure 3. The impact of the nucleation layer on pore stability
A) MSV with and without a nucleation layer (MSVxNL) were compared at various times
looking at the overall effect on size and shape (left) and their pores (right) on the front-side
where the nucleation layer is visible. Scale bars, left for particle is 1 *m; right for pores is 50
nm. B) Volume distribution of MSV and MSVxNL showing smaller sized for MSVxNL but
with comparable shifts in size with increased time. C) Flow cytometry verifying similar
patterns for size (forward scatter) and shape (side scatter) of the two MSV. D) ICP-AES
contrasting MSV versus MSVxNL to confirm minimal change in overall degradation of
MSV without nucleation layer.
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Figure 4. Influence of buffer in degradation of MSV
A) ICP-AES comparison of MSV, SP (left column) and LP (right column), degradation in
CCM and saline solution. B) SEM images showing MSV degradation in CCM (left) and
saline (right) solutions at various time points. C) Volume distributions of MSV in CCM
(top) and saline (bottom) are plotted at various time points relating the shifts in size.
Distributions are offset on the yaxis to highlight differences between time points. The results
are shown as mean ± SD. Asterisks denote where the difference was statistically significant
compared to Saline. *** p < 0.001.
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Figure 5. Degradation effect of MSV in varying pH environments
A) Schematic showing possible interactions between the MSV surface and hydroxyl groups.
Hydroxyl ions of an alkaline solution weaken the surface of the MSV forming bioinert
silicic acid. B) Flow cytometry exhibiting distinct patterns and changes in size (forward
scatter) and shape (side scatter) exposed to the varying pH environments. C) Flow cytometer
counts collected at various time points to show degradation rates of MSV at pHs between 9
and 12.
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Figure 6. Cellular architecture and biocompatibility of MSV degradation products
A) The microfilaments (green) and nucleus (blue) of HUVEC were stained to interpret the
effect of exposing MSV fragments. Control and non-degraded MSV were used to compare
cytoskeletal structure. B) An MTT assay to demonstrate the continued proliferation of
HUVEC after internalizing oxidized (left) and APTES (right) degradation products of MSV
with varying porosities (SP-XLP). Proliferation of HUVEC was compared to sterile PBS,
the buffer used to degrade the MSV. The results are shown as mean ± SD. C) Cell cycle
analysis at 48 hours after introduction to degradation products of MSV. The cell cycle of
HUVEC was conserved independent of surface (oxidized and APTES) and porosity (SP and
LP).
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Table 1
MSV Characteristics
Name of MSV Porosity (%) Pore size (nm)
Non-Porous (NP) 0 0
Small Pore (SP) 46 10.1
Medium Pore (MP) 51 15.2
Large Pore (LP) 66 26.3
Extra Large Pore (XLP) 82 51.3
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